Lytix Biopharma’s abstract with preliminary interim Phase II data from the ATLAS-IT-05 study is published

16 Oct 2023 08:51 CEST

Oslo, 16 October 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext
Growth Oslo: LYTIX), a clinical stage immuno-oncology company, announces that an
abstract for a poster presentation at the ESMO Congress 2023 today has been
published online on the ESMO website.

After the submission of the abstract, the data set to be included in the poster
presentation on Monday 23 October was expanded. The majority of the patients are
still early in the treatment course, and responses will continue to evolve.


Details for the poster session are as follows:
Abstract Title: Intratumoral injection of LTX-315 in combination with
pembrolizumab in patients with advanced melanoma refractory to prior PD-1/PD-L1
therapy: interim results from the ATLAS-IT-05 trial
Poster Number: 1051P
Session: Investigational immunotherapy
Session Date and Time: Monday, October 23, 2023
Session Location: Hall 8



Dr. Øystein Rekdal, Chief Executive Officer at Lytix Biopharma, commented: “The
ATLAS-IT-05 study presents an opportunity to demonstrate whether LTX-315 in
combination with pembrolizumab treatment could enhance the clinical outcome in
PD-1 / PD-L1 refractory melanoma patients. We are looking forward to presenting
interim data at ESMO, even though this is very early in the study as the
treatment cycles have not been completed for the majority of the patients
included.”

***

For more information, please contact:
Gjest Breistein, CFO: gjest.breistein@lytixbiopharma.com
Ole Peter Nordby, Head of IR & Communications Manager:
ole.peter.nordby@lytixbiopharma.com
Optimum Strategic Communications: Nick Bastin, Vici Rabbetts:
lytix@optimumcomms.com

Lytix in brief:
Based in Oslo, Norway, Lytix Biopharma is a clinical stage immuno-oncology
company developing novel cancer immunotherapies, an area within cancer therapy
that is aimed at activating the patient’s immune system to fight cancer. The
Company’s technology is based on pioneering research in “host defense peptides”
– nature’s first line of defense towards foreign pathogens. Lytix Biopharma’s
lead product, LTX-315, is a first-in-class molecule representing a new and
superior therapeutic principle to kill cancer cells and boost anti-cancer
immunity, with the potential to be the ideal combination partner with other
types of immunotherapies. LTX-315`s dual mode of action allows cytotoxic T cells
to infiltrate tumors and recognize and attack cancer cells. The Company was
listed on Euronext Growth in Oslo in June 2021, following a private placement
covered by investors including PBM Capital, a US based, healthcare-focused
investment firm.

More information:
Access the news on Oslo Bors NewsWeb site